The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α

https://dx.doi.org/10.1111/liv.13111

Post author By Orr J G, Currie C J, Berni E R, Goel A, Moriaty K J, Sinha A, Gordon F H, Dethier A, Dillon J F, Clark K, Richardson P, Patel V, Shawcross D L, Preedy H, Aspinall R J and Hudson M
Post date 7 March 2016

Orr J G, Currie C J, Berni E R, Goel A, Moriarty K J, Sinha A, Gordon F, Dethier A, Dillon J F, Clark K, Richardson P, Middleton P, Patel V, Shawcross D, Preedy H, Aspinall R J, Hudson M. 07 Mar 2016

Orr J G

Currie C J

Berni E R

Goel A

Moriaty K J

Sinha A

Gordon F H

Dethier A

Dillon J F

Clark K

Richardson P

Patel V

Shawcross D L

Preedy H

Aspinall R J

Hudson M

Transforming real-world data into transparent, reliable, and reliable real-world evidence

44 (0) 2920 782856

enquiries@humandatasciences.com

24 Wordsworth Avenue, Cardiff, CF24 3FR United Kingdom

Copyright Pharmatelligence Limited (trading as Human Data Sciences) is a Private Limited Company (PLC) registered in England and Wales with Company Number 7107514.

Livingstone® is a Trusted Research Environment (TRE)

Quick Links

Transforming real-world data into transparent, reliable, and replicable real-world evidence

44 (0) 2920 782856

instantRWE@humandatasciences.com

The Global Pharma Research Centre,
24 Wordsworth Avenue, Cardiff, CF24 3FR United Kingdom

Copyright Pharmatelligence Limited (trading as Human Data Sciences) is a Private Limited Company (PLC) registered in England and Wales with Company Number 7107514.

Livingstone^® is a Trusted Research Environment (TRE)

Web Design – Create Summit

Site by Create Summit